| Dr Natalie P Higgins, MD | |
|
1800 116th Ave Ne Ste 102, Bellevue, WA 98004 | |
| (425) 451-3710 | |
| (425) 451-2636 |
| Full Name | Dr Natalie P Higgins |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology - Otolaryngology/facial Plastic Surgery |
| Location | 1800 116th Ave Ne Ste 102, Bellevue, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740393461 | NPI | - | NPPES |
| 2016912 | Medicaid | WA | |
| MD60174057 | Other | WA | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 60174057 (Washington) | Secondary |
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | MD60174057 (Washington) | Primary |
| Entity Name | King County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.
Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."
› Verified 4 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.
Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."
› Verified 4 days ago
| Entity Name | The Everett Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831186766 PECOS PAC ID: 6406752153 Enrollment ID: O20031211000922 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.
Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Natalie P Higgins, MD 1800 116th Ave Ne Ste 102, Bellevue, WA 98004-3043 Ph: (425) 451-3710 | Dr Natalie P Higgins, MD 1800 116th Ave Ne Ste 102, Bellevue, WA 98004 Ph: (425) 451-3710 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.
Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."
› Verified 4 days ago
Dr. Jonathan Chaim Kopelovich, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne, Suite 915, Bellevue, WA 98004 Phone: 425-454-3938 Fax: 425-454-2568 | |
Dr. James Matthew Ridgway, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 1231 116th Ave Ne Ste 900, Bellevue, WA 98004 Phone: 425-365-4970 Fax: 425-365-4969 | |
Eric T Waterman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 12402 Se 38th St Ste 201, Bellevue, WA 98006 Phone: 425-656-4200 Fax: 425-656-4258 | |
Dr. Eric Andrew Eisen, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne Ste 930, Bellevue, WA 98004 Phone: 425-688-1916 Fax: 425-688-1901 | |
Dr. Adrienne Maria Laury, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne Ste 915, Bellevue, WA 98004 Phone: 425-454-3938 Fax: 425-454-2568 | |
Jan Zemplenyi, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1260 116th Ave Ne, Suite 110, Bellevue, WA 98004 Phone: 425-455-7225 Fax: 425-455-0045 | |
Dr. Eric F Pinczower, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1800 116th Ave Ne, Suite 102, Bellevue, WA 98004 Phone: 425-451-3710 Fax: 425-451-2636 |